With Positive Study Results, Genomic Health on Track to Launch Oncotype DX Prostate Cancer in 2013 | GenomeWeb

Genomic Health announced this week it is on track for a 2013 launch of its Oncotype Dx test to help doctors distinguish between aggressive and indolent prostate cancer.

According to the company, a large clinical validation trial performed in collaboration with the University of California, San Francisco, has met its primary endpoint demonstrating that the Oncotype DX prostate cancer risk score can discern which early-stage patients are at risk of disease progression. The test analyzes tumor tissue prostate needle biopsies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.